Table 1.
Characteristics of adult patients who underwent PB and melphalan based first AHCT for multiple myeloma with t(11;14) abnormality and reported with CIBMTR in 2008–2016
| Characteristic | AA with t(11;14) N=117 |
AA w/o t(11;14) N=968 |
Whites with t(11;14) N=266 |
Whites w/o t(11;14) N=2,187 |
|---|---|---|---|---|
| No. of centers | 45 | 98 | 71 | 115 |
| Median age (range) | 57 (31–75) | 58 (20–78) | 61 (30–79) | 60 (23–80) |
| Gender, Male (%) | 63 (54) | 463 (48) | 143 (54) | 1323 (60) |
| Karnofsky score <90 | 57 (49) | 512 (53) | 107 (40) | 882 (40) |
| HCT-CI score ≥ 3 | 51 (44) | 410 (42) | 103 (39) | 729 (33) |
| Insurance | ||||
| Medicare/Medicaid | 44 (38) | 403 (42) | 94 (35) | 723 (33) |
| Employer/Private Insurance | 73 (62) | 542 (56) | 169 (64) | 1438 (66) |
| Not reported | 0 | 23 (2) | 3 (1) | 26 (1) |
| Education | ||||
| High school or less | 54 (46) | 465 (48) | 91 (34) | 873 (40) |
| College | 37 (32) | 266 (27) | 84 (32) | 650 (30) |
| Graduate school | 5 (4) | 26 (3) | 20 (8) | 90 (4) |
| Not reported | 21 (18) | 211 (22) | 71 (27) | 574 (26) |
| Marriage status | ||||
| Single/Divorced | 46 (39) | 393 (41) | 67 (25) | 456 (21) |
| Married, live with partner | 66 (56) | 530 (55) | 193 (73) | 1684 (77) |
| Not reported | 5 (4) | 45 (5) | 6 (2) | 47 (2) |
| Employment status | ||||
| Unemployed | 45 (38) | 316 (33) | 64 (24) | 455 (21) |
| Employed | 38 (32) | 295 (30) | 89 (33) | 756 (35) |
| Retired | 29 (25) | 265 (27) | 89 (33) | 758 (35) |
| Not reported | 5 (4) | 92 (10) | 24 (9) | 218 (10) |
| Immunochemical subtype | ||||
| IgG | 62 (53) | 640 (66) | 116 (44) | 1294 (59) |
| IgA | 18 (15) | 154 (16) | 43 (16) | 469 (21) |
| Light chain | 32 (27) | 163 (17) | 92 (35) | 379 (17) |
| Non-secretory | 3 (3) | 8 (1) | 6 (2) | 27 (1) |
| Others | 2 (2) | 3 (0) | 9 (3) | 18 (1) |
| Stage at diagnosis (ISS/DSS), stage III | 72 (62) | 534 (55) | 153 (58) | 1189 (54) |
| Cytogenetics | ||||
| No abnormality | 0 | 397 (41) | 0 | 918 (42) |
| t(11;14) only | 39 (33) | 0 | 75 (28) | 0 |
| t(11;14) + other standard risk | 53 (45) | 0 | 118 (44) | 0 |
| t(11;14) + other high risk | 25 (21) | 0 | 73 (27) | 0 |
| Standard risk | 0 | 339 (35) | 0 | 770 (35) |
| High risk abnormality (not t(11;14)) | 0 | 232 (24) | 0 | 499 (23) |
| Serum creatinine at diagnosis, mg/dl ≥ 2 mg/dl | 19 (16) | 140 (14) | 45 (17) | 266 (12) |
| Lines of induction chemotherapy, 1 | 77 (66) | 683 (71) | 162 (61) | 1487 (68) |
| Induction Chemotherapy | ||||
| Triples (VTD/VCD/VRD) | 88 (75) | 678 (70) | 196 (74) | 1320 (60) |
| Doublets (TD/RD/VD) | 24 (21) | 251 (26) | 63 (24) | 767 (35) |
| Other | 4 (3) | 30 (3) | 5 (2) | 79 (4) |
| Not reported | 1 (1) | 9 (1) | 2 (1) | 21 (1) |
| Disease status prior to transplant | ||||
| ≥VGPR | 45 (38) | 471 (49) | 103 (38) | 1002 (46) |
| ≤PR | 72 (62) | 495 (52) | 163 (62) | 1182 (54) |
| Not reported | 0 | 2 (0) | 0 | 3 (0) |
| Melphalan 200 mg/m2 conditioning | 83 (71) | 661 (68) | 197 (74) | 1594 (73) |
| Time from diagnosis to transplant | ||||
| <6 months | 28 (24) | 221 (23) | 80 (30) | 716 (33) |
| 6 – 12 months | 62 (53) | 468 (48) | 131 (49) | 999 (46) |
| 12 – 24 months | 14 (12) | 175 (18) | 38 (14) | 275 (13) |
| ≥ 24 months | 13 (11) | 104 (11) | 17 (6) | 197 (9) |
| Type of transplant | ||||
| Single HCT | 106 (91) | 928 (96) | 253 (95) | 2034 (93) |
| Tandem AutoHCT | 11 (9) | 40 (4) | 13 (5) | 153 (7) |
| Year of transplant | ||||
| 2008 | 9 (8) | 96 (10) | 36 (14) | 475 (22) |
| 2009 | 1 (1) | 53 (5) | 14 (5) | 168 (8) |
| 2010 | 10 (9) | 68 (7) | 7 (3) | 127 (6) |
| 2011 | 5 (4) | 47 (5) | 24 (9) | 201 (9) |
| 2012 | 2 (2) | 42 (4) | 27 (10) | 192 (9) |
| 2013 | 13 (11) | 92 (10) | 42 (16) | 316 (14) |
| 2014 | 20 (17) | 146 (15) | 31 (12) | 218 (10) |
| 2015 | 26 (22) | 196 (20) | 36 (14) | 261 (12) |
| 2016 | 31 (26) | 228 (24) | 49 (18) | 229 (10) |
| Median follow-up of survivors (range), months | 25 (4–79) | 27 (3–110) | 37 (4–111) | 51 (3–120) |
w/o; without, VTD; bortezomib (V), thalidomide (T), dexamethasone (D), VCD; bortezomib, cyclophosphamide (C), dexamethasone (D), VRD; bortezomib (V), lenalidomide (R), dexamethasone (D)